What are two major safety concerns with linezolid therapy?

What are two major safety concerns with linezolid therapy?

• A. Hepatotoxicity and QT prolongation
• B. Serotonin syndrome risk with serotonergic drugs and thrombocytopenia with prolonged use
• C. Nephrotoxicity and ototoxicity
• D. Photosensitivity and bone marrow suppression

Answer: (B)

Linezolid has two notable safety considerations that clinicians watch closely. Its ability to weakly inhibit monoamine oxidase means it can interact with serotonergic medicines (such as SSRIs, SNRIs, TCAs, MAO inhibitors, and certain analgesics), increasing the risk of serotonin syndrome, a potentially dangerous reaction that can involve confusion, autonomic instability, and neuromuscular changes. With longer courses, linezolid can cause bone marrow suppression, especially thrombocytopenia, along with possible anemia or leukopenia, so platelet and complete blood count monitoring is important during extended therapy. These two factors explain why the combination with serotonergic drugs and the risk of low platelets with prolonged use are the major safety concerns.

Linezolid has two notable safety considerations that clinicians watch closely. Its ability to weakly inhibit monoamine oxidase means it can interact with serotonergic medicines (such as SSRIs, SNRIs, TCAs, MAO inhibitors, and certain analgesics), increasing the risk of serotonin syndrome, a potentially dangerous reaction that can involve confusion, autonomic instability, and neuromuscular changes. With longer courses, linezolid can cause bone marrow suppression, especially thrombocytopenia, along with possible anemia or leukopenia, so platelet and complete blood count monitoring is important during extended therapy. These two factors explain why the combination with serotonergic drugs and the risk of low platelets with prolonged use are the major safety concerns.